Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need. We are currently focusing our development efforts on our immuno-oncology programs, which are conducted primarily through Duet BioTherapeutics Inc. (... Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need. We are currently focusing our development efforts on our immuno-oncology programs, which are conducted primarily through Duet BioTherapeutics Inc. (Duet), our majority-owned subsidiary. These programs include three distinctive complementary CpG-STAT3 inhibitors: Antisense ("DUET-101"); RNA silencing ("DUET-202"); and DNA-binding inhibitor ("DUET-301"). The Company may also seek to develop additional drug candidates and identify additional compelling technologies for potential acquisition, in-licensing and/or other similar transactions. Mostrar mais
Pergunte à ADVFN Intelligence (IA)
| Período | Var | Var % | Abe | Máx. | Mín. | Vol Méd. | VWAP diário | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0002 | 200 | 0.0001 | 0.0003 | 0.0001 | 3493 | 0.00012004 | CS |
| 4 | 0 | 0 | 0.0003 | 0.0003 | 0.0001 | 2239 | 0.00012133 | CS |
| 12 | 0.0001 | 50 | 0.0002 | 0.0003 | 1.0E-6 | 2030 | 0.000151 | CS |
| 26 | -0.0021 | -87.5 | 0.0024 | 0.0025 | 1.0E-6 | 4146 | 0.00086639 | CS |
| 52 | -0.0587 | -99.4915254237 | 0.059 | 0.06695 | 1.0E-6 | 7722 | 0.03608051 | CS |
| 156 | -0.0848 | -99.6474735605 | 0.0851 | 0.156 | 1.0E-6 | 25711 | 0.07973799 | CS |
| 260 | -0.0848 | -99.6474735605 | 0.0851 | 0.156 | 1.0E-6 | 25711 | 0.07973799 | CS |
Suporte: (11) 4950 5808 | suporte@advfn.com.br
Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições
Recursos principais
Premium
